HLS Therapeutics (TSE:HLS) Releases Quarterly Earnings Results

HLS Therapeutics (TSE:HLS) announced its quarterly earnings data on Thursday. The company reported C($0.05) earnings per share for the quarter, FiscalAI reports. The firm had revenue of C$20.06 million during the quarter. HLS Therapeutics had a negative net margin of 25.28% and a negative return on equity of 21.20%.

Here are the key takeaways from HLS Therapeutics’ conference call:

• Financial recovery: 2025 Adjusted EBITDA rose 18% to $19.6M, cash from operations increased 114% to $17.1M, and net debt fell ~23%, giving the company more flexibility for growth and capital allocation.
• Vascepa turnaround: Vascepa unit demand grew 23% in 2025 with a H2 inflection in new-to-brand prescriptions, and the product made a positive contribution to Adjusted EBITDA for the first time.
• NILEMDO launch and CV franchise build: NILEMDO is now available to wholesalers with a full sales-force launch planned for early April, private payer coverage expected over months and provincial listings targeted in early 2027, and management projects a CAD 50–100M peak sales opportunity for the bempedoic acid franchise.
• Conservative 2026 guidance: Management guided revenue of $56M–$60M and Adjusted EBITDA of $18.5M–$21M (essentially flat), reflecting conservative NILEMDO assumptions and front‑loaded launch investment that may limit near‑term upside.
• Near‑term commercial and reimbursement risks: Clozaril faced pricing/GPO pressure in Ontario that may cause some 2026 headwinds, public payer listings for NILEMDO remain pending (target 2027), and NEXLIZET approval/timing and reimbursement outcomes — which affect milestone payments — are not yet finalized.

HLS Therapeutics Price Performance

HLS opened at C$4.29 on Friday. The company has a debt-to-equity ratio of 87.61, a quick ratio of 1.01 and a current ratio of 1.17. HLS Therapeutics has a 52-week low of C$3.90 and a 52-week high of C$5.77. The stock’s 50 day moving average price is C$4.56 and its 200-day moving average price is C$5.03. The stock has a market capitalization of C$134.17 million, a PE ratio of -9.53 and a beta of 0.48.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.